HOME >> MEDICINE >> NEWS
Mayo Clinic finds effective treatment with minimal side effects for non-renal lupus

ROCHESTER, Minn. -- Mayo Clinic investigators have found that the medication mycophenolate mofetil is effective for managing symptoms of systemic lupus erythematosus (SLE), the most common type of lupus, for patients whose SLE does not affect the kidneys. Importantly, the researchers say the drug is well tolerated and has fewer side effects than many other medications used to treat the disease.

"This would be considered a nice addition to medications we can use for these patients -- an alternative and widely applicable to many patients," says Kevin Moder, M.D., Mayo Clinic rheumatologist, who will present the findings at the American College of Rheumatology Annual Scientific Meeting in San Antonio, Texas (http://www.rheumatology.org/annual/index.asp).

Patients who have SLE, an autoimmune, inflammatory disease, may experience symptoms from fevers to joint pain to excessive fatigue to hair loss, among others. The disease also may affect major organs, and the kidneys are especially vulnerable. SLE affecting the kidneys is treated differently from non-renal SLE. Mycophenolate mofetil has been shown to be helpful in patients with lupus affecting the kidneys. The new Mayo Clinic research indicates, however, that the drug could help many more lupus patients.

Currently, there is no curative treatment for SLE. Also, many medications used to treat this disease have considerable side effects. For example, Dr. Moder explains that one currently available immunomodulatory treatment, cyclophosphamide, puts patients at risk for infertility and cancer.

"It's a significant step if the medication is effective but has fewer side effects than many medications currently used to treat lupus," says Dr. Moder.

Dr. Moder explains that while mycophenolate mofetil helps many patients, it's not 100 percent effective. He descr
'"/>


17-Oct-2004


Page: 1 2

Related medicine news :

1. Mayo Clinic discovers new pathway against pancreatic cancer
2. Mayo Clinic develops first genomic-based test to predict stroke from ruptured brain aneurysm
3. Mayo Clinic study sets threshold for valve repair surgery
4. Mayo Clinic researcher calls for improved newborn screening
5. Mayo Clinic study finds obese kidney donors face few increased risks
6. Mayo Clinic identifies key cellular process in prostate and other cancers
7. Clinical breast examination offers modest benefit to breast cancer screening program
8. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
9. Clinicians report missing patient information is common
10. Mayo Clinic discovers a key to low metabolism and major factor in obesity
11. Clinical trial of Etanercept for Wegeners disease shows no benefit

Post Your Comments:
(Date:4/25/2015)... 25, 2015 On Friday, April 17, ... Journal’s annual Best Implementation Award. This award is ... best use of RFID technology to improve its manufacturing, ... company that best demonstrates how RFID is delivering real ... RFID Journal Live! 2015 in San Diego, the RFID ...
(Date:4/24/2015)... As the nation recognizes the Month ... of these young men and women, the “Alaska – ... their Families” presents a special training session on Adverse ... a better understanding of the effect of childhood trauma ... – civilian and military – who provide services and ...
(Date:4/24/2015)... The 1975 have had an intense ... globe to theaters, festivals and TV performances. Now that they’ve ... their label, Dirty Hit Records, to provide clean drinking water ... launched Cadence & Cause website, this four-piece has ... and a signed photo card. Entries from this sweepstakes ...
(Date:4/24/2015)... Versailles, KY (PRWEB) April 24, 2015 ... Planning for Medical Field Professionals, today announced their exclusive ... their national Long Term Care Insurance distribution partner. , ... the Long Term Care Insurance benefits for associations, and ... Association for its Long Term Care Insurance member ...
(Date:4/24/2015)... Insuranceautoquote.info has released a new blog post ... , Lowering auto insurance prices is not difficult. ... better offers for their financial budget. Comparing prices by ... require any registration. , Comparing quotes can help ... agencies that sell coverage and this means that clients ...
Breaking Medicine News(10 mins):Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2Health News:Car Insurance Quotes Can Help Drivers Lower Their Premiums 2
(Date:4/23/2015)... NORTH CHICAGO, Ill. , April 24, 2015 /PRNewswire/ ... U.S. Food and Drug Administration (FDA) has accepted its ... the company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ... is for the treatment of adults with chronic genotype ... AbbVie,s regimen is the first all-oral, interferon-free therapy being ...
(Date:4/23/2015)... 2015 /CNW/ - Health Canada is working with the ... the safety information regarding the risk of serious cardiovascular ... products are used at high doses (at or above ... of use. Ibuprofen is a non-steroidal anti-inflammatory ... to reduce inflammation. The majority of ibuprofen products in ...
(Date:4/23/2015)... , Apr. 23, 2015 Surna, Inc. ... and distributes state-of-the art equipment and systems for ... commercial indoor cannabis cultivation, will host a shareholder ... April 27, 2015, at 4:15 PM Eastern Standard ... The conference call will be listen-in only, but ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 2Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 3Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 4Surna, Inc. Announces Shareholder Conference Call 2Surna, Inc. Announces Shareholder Conference Call 3
Cached News: